Innovation In the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?

POSPÍŠILOVÁ, Šárka, Lesley-Ann SUTTON, Jitka MALČÍKOVÁ, Eugen TAUSCH, Davide ROSSI, Emili MONTSERRAT, Carol MORENO, Kostas STAMATOPOULOS, Gianluca GAIDANO, Richard ROSENQUIST and Paolo GHIA. Innovation In the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go? Haematologica. PAVIA: FERRATA STORTI FOUNDATION, 2016, vol. 101, No 3, p. 263-265. ISSN 0390-6078. Available from: https://dx.doi.org/10.3324/haematol.2015.139246.

Basic information

• Original name: Innovation In the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?
• Authors: POSPÍŠILOVÁ, Šárka, Lesley-Ann SUTTON, Jitka MALČÍKOVÁ, Eugen TAUSCH, Davide ROSSI, Emili MONTSERRAT, Carol MORENO, Kostas STAMATOPOULOS, Gianluca GAIDANO, Richard ROSENQUIST and Paolo GHIA.
• Edition: Haematologica, PAVIA, FERRATA STORTI FOUNDATION, 2016, 0390-6078.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30200 3.2 Clinical medicine
• Country of publisher: Italy
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Impact factor: Impact factor: 7.702
• Organization unit: Central European Institute of Technology
• Doi: http://dx.doi.org/10.3324/haematol.2015.139246
• UT WoS: 000379392800016
• Keywords in English: CLONAL EVOLUTION; MUTATIONS; SURVIVAL; TRIAL; PROGRESSION; IMPACT; CLL
• Tags: EDITORIAL, MEDGENET

Abstract

T he prognostication of patients with chronic lympho- cytic leukemia (CLL) currently relies on both clinical and biological parameters (Figure 1). The prime exam- ple concerns the TP53 gene, whereby inactivation of TP53 , resulting from either a mutation or chromosome 17p deletion, is associated with a short time to progression, an early need for treatment, and an overall dismal outcome. 1,2 The presence of TP53 aberrations is also a strong predictor of treatment response, as patients carrying such lesions respond poorly to standard chemoimmunotherapy (CIT) (i.e. fludarabine, cyclophosphamide, and rituximab). 3 Although TP53 abnor- malities are infrequent at diagnosis (5%-10%), they are found in 40%-50% of advanced or therapy-refractory cases, hence underscoring the need to re-assess TP53 gene status as the dis- ease progresses and clones evolve.

Links

• ED1.1.00/02.0068, research and development project: Name: CEITEC - central european institute of technology
• NV15-30015A, research and development project: Name: Analýza klonální heterogenity chronické lymfocytární leukemie pomoci sekvenování nové generace genu pro B-buněčný receptor. Národní studie.
• NV15-31834A, research and development project: Name: Vliv selekce genomických poškození na průběh chronické lymfocytární leukémie